Chronic edema

OAKLAND, Calif., Nov. 25, 2024 /PRNewswire/ -- Koya Medical, a leading medical device company pioneering solutions in vascular care, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:50 pm ET. Koya CEO, Andy Doraiswamy, PhD, will share updates on the company's progress, including Dayspring, its novel integrative compression treatment for chronic edema in venous and lymphatic disorders, and its pipeline for addressing superficial and deep vein diseases. Koya recently expanded its clinical evidence with the publication of its latest randomized multicenter trial, TEAYS, in the Journal of Vascular Surgery. Dayspring met both primary and secondary endpoints and showed a broad range of superior clinical benefits for patients using Dayspring compared to standard of care. About Venous Disease and Lymphedema An estimated 20 million Americans live with lymphedema, a progressive, incurable condition where a buildup of protein-rich fluid causes painful swelling in the arm, leg, and/or other regions of the body. For most, lymphedema requires lifelong maintenance and various levels of therapy to control swelling and pain. Lymphedema can result from a variety of factors, including chronic venous disease, cancer, infection, and surgery. About Dayspring The Dayspring non-pneumatic compression treatment integrates multiple modalities of compression and mobility into an easy-to-use solution. It is FDA cleared and indicated to treat lymphedema, venous insufficiency, and chronic edema; it is commercially available in the United States. Visit Koya Medical LinkedIn at SOURCE Koya Medical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

OXFORD, England & IRVINE, Calif. & PASADENA, Calif.--( BUSINESS WIRE )--Rockley Photonics has announced the sampling of the complete Bioptx™ Biosensing Band and Platform to strategic customers and partners. The Bioptx™ Biosensing Band incorporates Rockley’s breakthrough short-wave infrared (SWIR) biosensing technology based on their proprietary photonic integrated circuit (PIC) chipset. By incorporating the SWIR spectrophotometer into a wearable capable of several days of measurement, Rockley has demonstrated continuous collection of spectral data which provides unique insights into tissue composition and dynamics. The platform delivers real-time streaming of the SWIR-based biomarkers of body temperature and hydration, alongside the LED-based photoplethysmography (PPG) biomarkers of heart rate, heart rate variability, respiratory rate, and blood oxygen saturation. Combined with the recently released Rockley Developer API, the platform creates a seamless solution for real-time monitoring of vital physiologic parameters. Dr. Stavros Kavouras, a Professor of Nutrition at the College of Health Solutions at Arizona State University and founding director of the Hydration Science Lab, which studies how water intake impacts health and performance, commented on the novel hydration biomarker that Rockley Photonics is developing. “Hydration is an underutilized biomarker that is critical for monitoring of both acute dehydration, such as in athletes, and chronic dehydration or under-hydration affecting metabolic, cognitive, cardiovascular, and renal health. By creating a spectroscopy-based technique to indicate hydration status, Rockley Photonics is developing an innovative new capability to improve people’s health and wellbeing.” Dr. Andrew Rickman, CEO and Chairman, spoke regarding this significant product milestone. “We are thrilled to usher in the next generation of health monitoring with wearable laser-based technology. Rockley has created the full technology stack from the design of the PIC, which forms the miniature spectrophotometer, to the full wearable integration and novel biomarker delivery. We have significantly progressed the SWIR-tissue measurement science and biomarker algorithms through IRB-approved human studies. As we have recently demonstrated with our non-invasive glucose sensing and cuffless blood pressure studies, laser-based biosensors will continue to expand and enhance our understanding of human health.” About Rockley Photonics Rockley is a global leader in photonics-based health monitoring, invested in discovering new ways to measure important biometrics using novel sensing techniques. Rockley is developing a comprehensive range of photonic integrated circuits, sensors, and full-stack solutions. From next-generation biosensing platforms to mobile health monitoring, Rockley is laying the foundation for a new era of precision medicine. Rockley believes that photonics will eventually become as pervasive as micro-electronics and has developed a platform with the power and flexibility needed to address the medical device and technology market through a wide variety of vertical applications. The company has partnered with numerous tier-1 customers, spanning a range of industries to deliver the complex optical systems required to bring transformational products to life. Rockley is dedicated to pushing the boundaries of what is possible with photonics technology to create new solutions for a wide range of comprehensive monitoring applications, with an aim to revolutionize how people manage their health.

EyeYon Medical announced today that it received CE mark approval for its EndoArt synthetic endothelium replacement implant. Tel Aviv, Israel-based EyeYon designed EndoArt to replace dysfunctional endothelium in patients awaiting human donor tissue as a first-line treatment for patients with chronic corneal edema, as patients with a nonfunctioning endothelium experience excess fluid flowing into the cornea, which can produce severe vision loss, pain and irreversible scarring of the human tissue. The implant enables doctors to treat endothelial-related chronic corneal edema with minimally invasive surgery. According to a news release, the system became the only ophthalmic device globally to receive both China’s Innovative Device Status and U.S. breakthrough device designation from the FDA. EndoArt proved its safety and effectiveness in clinical trials across Europe, while other clinical trials are currently underway in India and Israel. “We are proud to receive CE mark for our unique EndoArt implant, which is set to transform the way patients with chronic corneal edema are treated,” EyeYon Medical co-founder & CEO Nahum Ferera said in the release. “This important approval enables us to work closely with healthcare providers across Europe to help patients who suffer from corneal edema regain their sight and quality of life with a simple, accessible and cutting-edge solution. We would like to thank our European partners for the journey we shared over the past years to advance our technology in the continent.”